Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 101

1.

Active specific immunization in the treatment of patients with melanoma.

Mastrangelo MJ, Maguire HC Jr, Sato T, Nathan FE, Berd D.

Semin Oncol. 1996 Dec;23(6):773-81. Review.

PMID:
8970602
3.

Dendritic cells loaded with killed allogeneic melanoma cells can induce objective clinical responses and MART-1 specific CD8+ T-cell immunity.

Palucka AK, Ueno H, Connolly J, Kerneis-Norvell F, Blanck JP, Johnston DA, Fay J, Banchereau J.

J Immunother. 2006 Sep-Oct;29(5):545-57.

PMID:
16971810
4.

Clinical response after intradermal immature dendritic cell vaccination in metastatic melanoma is associated with immune response to particulate antigen.

Smithers M, O'Connell K, MacFadyen S, Chambers M, Greenwood K, Boyce A, Abdul-Jabbar I, Barker K, Grimmett K, Walpole E, Thomas R.

Cancer Immunol Immunother. 2003 Jan;52(1):41-52. Epub 2002 Nov 13.

PMID:
12536239
5.

Phase I trial of a MART-1 peptide vaccine with incomplete Freund's adjuvant for resected high-risk melanoma.

Wang F, Bade E, Kuniyoshi C, Spears L, Jeffery G, Marty V, Groshen S, Weber J.

Clin Cancer Res. 1999 Oct;5(10):2756-65.

6.

M-Vax: an autologous, hapten-modified vaccine for human cancer.

Berd D.

Expert Rev Vaccines. 2004 Oct;3(5):521-7. Review.

PMID:
15485331
7.

Adjuvant therapy of melanoma.

Agarwala SS, Kirkwood JM.

Semin Surg Oncol. 1998 Jun;14(4):302-10. Review.

PMID:
9588723
8.

Allogeneic and autologous melanoma vaccines: where have we been and where are we going?

Sondak VK, Sabel MS, Mulé JJ.

Clin Cancer Res. 2006 Apr 1;12(7 Pt 2):2337s-2341s. Review.

9.

Results of clinical trials with an allogenic melanoma tumor cell lysate vaccine: Melacine.

Sondak VK, Sosman JA.

Semin Cancer Biol. 2003 Dec;13(6):409-15. Review.

PMID:
15001159
10.

Immunopharmacologic analysis of an autologous, hapten-modified human melanoma vaccine.

Berd D, Sato T, Maguire HC Jr, Kairys J, Mastrangelo MJ.

J Clin Oncol. 2004 Feb 1;22(3):403-15. Epub 2003 Dec 22.

PMID:
14691123
11.

Immunogenicity, including vitiligo, and feasibility of vaccination with autologous GM-CSF-transduced tumor cells in metastatic melanoma patients.

Luiten RM, Kueter EW, Mooi W, Gallee MP, Rankin EM, Gerritsen WR, Clift SM, Nooijen WJ, Weder P, van de Kasteele WF, Sein J, van den Berk PC, Nieweg OE, Berns AM, Spits H, de Gast GC.

J Clin Oncol. 2005 Dec 10;23(35):8978-91. Epub 2005 Oct 31.

PMID:
16260696
12.

Tumoral and immunologic response after vaccination of melanoma patients with an ALVAC virus encoding MAGE antigens recognized by T cells.

van Baren N, Bonnet MC, Dréno B, Khammari A, Dorval T, Piperno-Neumann S, Liénard D, Speiser D, Marchand M, Brichard VG, Escudier B, Négrier S, Dietrich PY, Maraninchi D, Osanto S, Meyer RG, Ritter G, Moingeon P, Tartaglia J, van der Bruggen P, Coulie PG, Boon T.

J Clin Oncol. 2005 Dec 10;23(35):9008-21. Epub 2005 Aug 1.

PMID:
16061912
13.

[General principles and first clinical trials of therapeutic vaccines against cancer].

Baurain JF, Van der Bruggen P, Van den Eynde BJ, Coulie PG, Van Baren N.

Bull Cancer. 2008 Mar;95(3):327-35. doi: 10.1684/bdc.2008.0588. Review. French.

14.

Sequential immunization of melanoma patients with GD3 ganglioside vaccine and anti-idiotypic monoclonal antibody that mimics GD3 ganglioside.

Chapman PB, Wu D, Ragupathi G, Lu S, Williams L, Hwu WJ, Johnson D, Livingston PO.

Clin Cancer Res. 2004 Jul 15;10(14):4717-23.

15.
16.

Antibody-based vaccines for the treatment of melanoma.

Lutzky J, Gonzalez-Angulo AM, Orzano JA.

Semin Oncol. 2002 Oct;29(5):462-70. Review.

PMID:
12407511
17.
18.

Dynamic changes of specific T cell responses to melanoma correlate with IL-2 administration.

Andersen MH, Gehl J, Reker S, Pedersen LØ, Becker JC, Geertsen P, thor Straten P.

Semin Cancer Biol. 2003 Dec;13(6):449-59. Review.

PMID:
15001164
19.

Effect of the dose and composition of an autologous hapten-modified melanoma vaccine on the development of delayed-type hypersensitivity responses.

Berd D, Sato T, Mastrangelo MJ.

Cancer Immunol Immunother. 2002 Aug;51(6):320-6. Epub 2002 Jun 6.

PMID:
12111120
20.

Melanoma-specific tumor-infiltrating lymphocytes but not circulating melanoma-specific T cells may predict survival in resected advanced-stage melanoma patients.

Haanen JB, Baars A, Gomez R, Weder P, Smits M, de Gruijl TD, von Blomberg BM, Bloemena E, Scheper RJ, van Ham SM, Pinedo HM, van den Eertwegh AJ.

Cancer Immunol Immunother. 2006 Apr;55(4):451-8. Epub 2005 Jul 21.

PMID:
16034562

Supplemental Content

Support Center